New drug IBI3031 enters first human trial for thyroid eye disease

NCT ID NCT07622368

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This early-stage trial tests the safety and tolerability of a new drug called IBI3031 in 66 people with moderate-to-severe active thyroid eye disease. Participants will receive either the drug or a placebo by injection or infusion. The study aims to find the right dose and check for side effects, but it is too early to know if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3031
What this could lead to: If successful, this could point toward a new treatment option for thyroid eye disease, potentially reducing symptoms like bulging eyes and double vision.
What could go wrong: This is an early Phase 1 trial with only 66 participants, focused on safety. It may not show clear benefit, and side effects are unknown. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

Contacts and locations

Locations

the First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.